Current Oncology, Volume 17, Issue 5

Background: In 2005, bevacizumab was approved by Health Canada for patients with metastatic colorectal cancer (mcrc). Newfoundland and Labrador was one of the first Canadian provinces to fund this agent in combination with FOLFIRI (irinotecan, 5-fluo...

Purpose: Most male breast cancer tumours are hormone receptor–positive; the patients therefore receive endocrine therapy. There is, however, a paucity of published data on toxicities experienced by male breast cancer patients who are prescribed endoc...

Imagine a society in which patients are routinely euthanized—whether they want their lives to end or not—if their suffering cannot be alleviated without dulling their consciousness, eliminating their in-dependence, or threatening their di...

Purpose: Radiation-induced dermatitis is a common side effect of breast irradiation, with hypofractionation being a well-known risk factor. In the context of the widespread adoption of hypofractionated breast radiotherapy, we evaluated the effect of...

Interest has been increasing in the use of androgen deprivation therapy (adt) combined with radiation therapy (rt) in the management of localized prostate cancer. Preclinical studies have provided some rationale for the use of this combination. In pa...

In 1976, Peter Nowell, following observations of cytogenetic heterogeneity in a population of cancer-ous cells, proposed that this genetic diversity could be explained by hypothesizing that these cells are subject to evolutionary forces[...

After the discovery of the breast cancer–associated genes BRCA1 in 1994 and BRCA2 in 1995, genetic testing was introduced into clinical practice in North America and Europe[...]

Extramammary Paget disease (EMPD) is a rare skin disease commonly found in the anogenital region. In this study, we aimed to identify EMPD patients seen in the non-melanoma skin cancer clinic at Odette Cancer Centre and to describe the treatments del...

The words “personalized medicine” are used daily now in cancer care and research conversations. But what do those words really mean to us as patients, caregivers, physicians, managers of the health system, or researchers? Do we know how personalized...

Spindle-cell differentiation in ameloblastic carcinoma is a rare event. Although reported by many authors, it was first described as a separate entity in 1999 by Slater under the heading “low-grade spindle-cell ameloblastic carcinoma.” Here, we repor...